Bernhard J. Eigl

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Urology, Genitourinary Cancer, Medicine +7

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology · 2009 · 2.1K citations · Full text

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

Matti Annala, Gillian Vandekerkhove, Daniel Khalaf et al. · Cancer Discovery · 2018 · 507 citations · Full text

Pathology, Rapid Resistance, Invasive Biomarkers +17

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, Michiel S. van der Heijden, Daniel Castellano et al. · The Lancet Oncology · 2020 · 485 citations · Full text

Surgical Oncology, Urology, Metastatic Urothelial Carcinoma +8

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

Daniel Khalaf, Matti Annala, Sinja Taavitsainen et al. · The Lancet Oncology · 2019 · 338 citations

Urology, Oncology, Optimal Sequencing +8